Skip to Content

How does Besponsa work to treat acute lymphoblastic leukemia (ALL)?

Medically reviewed by Drugs.com Last updated on Sep 30, 2019.

Official Answer

by Drugs.com

Besponsa works by binding to B-cell ALL cancer cells that express the CD22 antigen and blocking the growth of cancerous cells.

Besponsa (inotuzumab ozogamicin), from Pfizer, is a CD22 monoclonal antibody and calicheamicin cytotoxic agent conjugate for relapsed or refractory B-cell acute lymphoblastic leukemia (ALL) in adults. 

Related Medical Questions

Drug Information

Related Support Groups

Hide